Analysis of Globotriaosylceramide (Gb3) in Liquid Urine: A Straightforward Assay Using Tandem Mass Spectrometry

Michel Boutin, Bruno Maranda, Paula J. Waters
{"title":"Analysis of Globotriaosylceramide (Gb3) in Liquid Urine: A Straightforward Assay Using Tandem Mass Spectrometry","authors":"Michel Boutin,&nbsp;Bruno Maranda,&nbsp;Paula J. Waters","doi":"10.1002/cpz1.1087","DOIUrl":null,"url":null,"abstract":"<p>Fabry disease (FD) is a lysosomal storage disorder caused by variants in the <i>GLA</i> gene encoding α-galactosidase A, an enzyme required for catabolism of globotriaosylceramide (Gb<sub>3</sub>). Accumulation of Gb<sub>3</sub> in patients’ cells, tissues, and biological fluids causes clinical manifestations including ventricular hypertrophy, renal insufficiency, and strokes. This protocol describes a methodology to analyze urinary Gb<sub>3</sub> and creatinine. Samples are diluted with an internal standard solution containing Gb<sub>3</sub>(C17:0) and creatinine-D<sub>3</sub>, centrifuged, and directly analyzed by ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) using an 8.7-min method. Eight Gb<sub>3</sub> isoforms [C16:0, C18:0, C20:0, C22:1, C22:0, C24:1, C24:0, and (C24:0)OH] are analyzed and the total is normalized to creatinine. Confirmation ions are monitored to detect potential interferences. The Gb<sub>3</sub> limit of quantification is 0.023 µg/ml. Its interday coefficients of variation (3 concentrations measured) are ≤15.4%. This method minimizes matrix effects (≤6.5%) and prevents adsorption or precipitation of Gb<sub>3</sub>. Urine samples are stable (bias &lt;15%) for 2 days at 21°C, 7 days at 4°C, and 4 freeze/thaw cycles, whereas prepared samples are stable for 5 days at 21°C, and 14 days at 4°C. The Gb<sub>3</sub>/creatinine age-related upper reference limits (mean + 2 standard deviations) are 29 mg/mol creatinine (&lt;7 years) and 14 mg/mol creatinine (≥7 years). This simple, robust protocol has been fully validated (ISO 15189) and provides a valuable tool for diagnosis and monitoring of FD patients. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC.</p><p><b>Basic Protocol</b>: Analysis of urinary globotriaosylceramide (Gb<sub>3</sub>) and creatinine by UHPLC-MS/MS</p><p><b>Support Protocol 1</b>: Preparation of the urinary quality controls</p><p><b>Support Protocol 2</b>: Preparation of the urine matrix used for the Gb<sub>3</sub> calibration curve</p><p><b>Support Protocol 3</b>: Preparation of the Gb<sub>3</sub> calibrators</p><p><b>Support Protocol 4</b>: Preparation of the working solution containing the internal standards</p><p><b>Support Protocol 5</b>: Preparation of the creatinine calibrators</p><p><b>Support Protocol 6</b>: Preparation of the UHPLC solutions and mobile phases</p>","PeriodicalId":93970,"journal":{"name":"Current protocols","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpz1.1087","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protocols","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpz1.1087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Fabry disease (FD) is a lysosomal storage disorder caused by variants in the GLA gene encoding α-galactosidase A, an enzyme required for catabolism of globotriaosylceramide (Gb3). Accumulation of Gb3 in patients’ cells, tissues, and biological fluids causes clinical manifestations including ventricular hypertrophy, renal insufficiency, and strokes. This protocol describes a methodology to analyze urinary Gb3 and creatinine. Samples are diluted with an internal standard solution containing Gb3(C17:0) and creatinine-D3, centrifuged, and directly analyzed by ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) using an 8.7-min method. Eight Gb3 isoforms [C16:0, C18:0, C20:0, C22:1, C22:0, C24:1, C24:0, and (C24:0)OH] are analyzed and the total is normalized to creatinine. Confirmation ions are monitored to detect potential interferences. The Gb3 limit of quantification is 0.023 µg/ml. Its interday coefficients of variation (3 concentrations measured) are ≤15.4%. This method minimizes matrix effects (≤6.5%) and prevents adsorption or precipitation of Gb3. Urine samples are stable (bias <15%) for 2 days at 21°C, 7 days at 4°C, and 4 freeze/thaw cycles, whereas prepared samples are stable for 5 days at 21°C, and 14 days at 4°C. The Gb3/creatinine age-related upper reference limits (mean + 2 standard deviations) are 29 mg/mol creatinine (<7 years) and 14 mg/mol creatinine (≥7 years). This simple, robust protocol has been fully validated (ISO 15189) and provides a valuable tool for diagnosis and monitoring of FD patients. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC.

Basic Protocol: Analysis of urinary globotriaosylceramide (Gb3) and creatinine by UHPLC-MS/MS

Support Protocol 1: Preparation of the urinary quality controls

Support Protocol 2: Preparation of the urine matrix used for the Gb3 calibration curve

Support Protocol 3: Preparation of the Gb3 calibrators

Support Protocol 4: Preparation of the working solution containing the internal standards

Support Protocol 5: Preparation of the creatinine calibrators

Support Protocol 6: Preparation of the UHPLC solutions and mobile phases

Abstract Image

分析液体尿液中的 Globotriaosylceramide (Gb3):使用串联质谱法进行直接测定。
法布里病(FD)是一种溶酶体贮积症,由编码α-半乳糖苷酶 A 的 GLA 基因变异引起,α-半乳糖苷酶 A 是分解球糖基甘油酰胺(Gb3)所需的一种酶。Gb3 在患者的细胞、组织和生物液体中积累会导致心室肥大、肾功能不全和中风等临床表现。本方案介绍了分析尿液中 Gb3 和肌酐的方法。样本用含有 Gb3(C17:0)和肌酐-D3 的内标溶液稀释,离心,然后直接用超高效液相色谱-串联质谱(UHPLC-MS/MS)分析,分析时间为 8.7 分钟。分析八种 Gb3 异构体[C16:0、C18:0、C20:0、C22:1、C22:0、C24:1、C24:0 和 (C24:0)OH],并将总量归一化为肌酐。监测确认离子以检测潜在的干扰。Gb3 的定量限为 0.023 µg/ml。其日间变异系数(测定 3 个浓度)≤15.4%。该方法最大程度地减少了基质效应(≤6.5%),防止了 Gb3 的吸附或沉淀。尿样是稳定的(偏差 3/肌酐年龄相关参考上限(平均值 + 2 个标准差)为 29 mg/mol 肌酐 (3)),通过 UHPLC-MS/MS 检测肌酐 支持方案 1:制备尿液质量控制 支持方案 2:制备用于 Gb3 校准曲线的尿液基质 支持方案 3:支持程序 4:制备含有内标物的工作溶液 支持程序 5:制备肌酐校准物 支持程序 6:制备超高效液相色谱溶液和流动相。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信